Treatment of Intractable Cancer Pain with Resiniferatoxin — An Interim Study
Intrathecal RTX is a single-administration, opioid-sparing analgesic in patients with intractable cancer pain. There were expected and unexpected AEs of various grades with an encouraging initial impact on pain. (Funded by the Intramural Research Program of the National Institutes of Health Clinical Center and others; ClinicalTrials.gov number, NCT00804154).
Authors
- Christina Hayes
- Michael J. Iadarola (ORCID: https://orcid.org/0000-0001-7188-9810)
- Christine Alewine (ORCID: https://orcid.org/0000-0003-1661-0957)
- John A. Butman (ORCID: https://orcid.org/0000-0002-1547-9195)
- Nusrat Rabbee
- Matthew R. Sapio (ORCID: https://orcid.org/0000-0002-8855-5419)
- Andrew J. Mannes (ORCID: https://orcid.org/0000-0001-5834-5667)
- John D. Heiss (ORCID: https://orcid.org/0000-0002-3890-0165)
- Ann Berger (ORCID: https://orcid.org/0000-0002-3764-0293)
- Tracy S. Williams
- Marybeth S. Hughes
Institutions
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- National Institute of Neurological Disorders and Stroke (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
- National Institutes of Health Clinical Center (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1056/evidoa2400423
- Citations
- 11
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.81